Pulmotech MAA Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The pulmotech MAA market research report is one of a series of new reports that provides pulmotech MAA market statistics, including pulmotech MAA industry global market size, regional shares, competitors with a pulmotech MAA market share, detailed pulmotech MAA market segments, market trends and opportunities, and any further data you may need to thrive in the pulmotech MAA industry. This pulmotech MAA market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to the increasing prevalence of respiratory diseases, technological advancements in diagnostic imaging, growing healthcare investments in emerging markets, rising demand for non-invasive diagnostic techniques, and the aging population. Major trends in the forecast period include increasing adoption of hybrid imaging systems, expansion of personalized and precision medicine, technological advancements in radiopharmaceuticals, advancements in radiopharmaceuticals for pediatric and sensitive populations, and increasing focus on respiratory disease research.

The increasing prevalence of respiratory diseases is expected to drive the growth of the Pulmotech MAA market in the coming years. Respiratory diseases encompass a wide range of conditions that affect the lungs and the broader respiratory system, including the airways, lungs, and respiratory muscles. A combination of factors such as environmental pollution, lifestyle changes, an aging population, and advances in diagnostic methods contributes to the rising prevalence of respiratory diseases. Pulmotech MAA aids in the diagnosis and management of chronic respiratory conditions by enhancing pulmonary imaging to assess lung function and detect abnormalities such as perfusion deficits. For example, a report from the Australian Institute of Health and Welfare in June 2024 estimated that around 8.5 million people in Australia, or 34% of the population, were living with chronic respiratory conditions, including 2.8 million with asthma and 638,000 with chronic obstructive pulmonary disease (COPD). As respiratory diseases become more widespread, the demand for Pulmotech MAA is expected to grow.

The increasing prevalence of chronic diseases is also expected to contribute to the growth of the Pulmotech MAA market. Chronic diseases are long-lasting conditions that can persist for years or even a lifetime, and their prevalence is rising due to lifestyle changes, an aging population, and environmental factors. Pulmotech MAA plays a critical role in managing these conditions, particularly those affecting the lungs, by providing precise pulmonary perfusion imaging. This allows for better diagnosis and management of disorders such as pulmonary embolism and other lung-related diseases. For instance, according to the Australian Institute of Health and Welfare, the death rate from chronic diseases in Australia increased from 459 deaths per 100,000 population in 2021 to 490 in 2022. This growing prevalence of chronic diseases is expected to fuel the demand for Pulmotech MAA.

The growing aging population is another key factor expected to drive the expansion of the Pulmotech MAA market. The proportion of elderly individuals, typically aged 65 and older, is increasing as life expectancy rises due to advancements in healthcare, improved living conditions, and better chronic disease management. Pulmotech MAA supports the aging population by providing detailed pulmonary imaging that helps diagnose and monitor age-related respiratory conditions, allowing for timely and accurate treatments. For example, statistics from the Population Reference Bureau in January 2024 predicted that the number of Americans aged 65 and older will increase from 58 million in 2022 to 82 million by 2050, marking a 47% increase. As the elderly population grows, the demand for pulmonary diagnostic tools such as Pulmotech MAA will likely increase.

The key company operating in the pulmotech maa market is Curium Pharma.

North America was the largest region in the pulmotech MAA market in 2024. The regions covered in pulmotech MAA report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pulmotech MAA market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Pulmotech MAA is a radiopharmaceutical agent used in lung scintigraphy to assess pulmonary perfusion. It contains technetium Tc 99m-labeled aggregated human serum albumin particles. When administered intravenously, these particles temporarily lodge in the lung capillaries, allowing for imaging of blood flow in the lungs.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary applications of Pulmotech MAA include the diagnosis of pulmonary embolism (PE), preoperative assessments, evaluation of lung transplant viability, chronic respiratory disease assessment, and clinical research. Pulmonary embolism occurs when a blockage, typically caused by blood clots, affects one of the pulmonary arteries in the lungs. Pulmotech MAA is distributed through direct sales, distributors, and online platforms, and is used by various end users, including hospitals, research institutions, and diagnostic imaging centers.

The pulmotech MAA market consists of sales of radiopharmaceutical Kits, ready-to-use radiopharmaceuticals, imaging system integration, and emerging product variants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.